A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease.

This is a Phase 1b, randomized, double blind, placebo-controlled study and will be conducted in participants with established ASCVD and CKD with persistent inflammation (High-sensitivity C-reactive protein \[hsCRP\] \> 2 mg/L and eGlomerular filtration rate \[eGFR\] ≥ 30 to \< 60 mL/min/1.73m2). The participants will be randomized in the 1:1 ratio to either receive treatment with AZD4144 or placebo. The study will be comprised of: * A screening period of 28 days * Treatment period where each participant will either receive oral dose of AZD4144 or placebo for 28 days. * A follow-up visit (Day 35 ±1) and a Final Follow-up (on Day 56±1) post first dose administration. The total duration of the study will be approximately 12 weeks.